Skip to main content
PYXS logo

PYXS · Pyxis Oncology, Inc.

Track PYXS — free
$1.81 +0.13 (+7.74%) At close · Nov 20
Market Cap
$216.49M
Shares
119.61M
Volume · Nov 20 3.05M Avg daily vol (3M) 1.06M

Price & Indicators

 

Key stats

Close
$1.81
Fri 20 Nov
Open
$1.70
Fri 20 Nov
Average volume, 30 days
925K
shares a session
Short interest
4.5M
3.8% of shares · 5.8 days to cover
Day range
$1.70$1.99
Open $1.70 Close $1.81
52-week closing range
$1.06$5.34
Close $1.81 66.1% under the high
Short volume, last session
41%
Last earnings
Nov 19, 2026
Latest filing
10-Q · Nov 5
Price history
Oct 2021 to Nov 2026

Up next

Jul 30, 2027 Est · unconfirmed · in 36 wks

Latest documents

2026
Nov 19
Current report 8-K Events of Nov 18
MICVO Shows 39% Confirmed Response Rate in Head and Neck

Pyxis Oncology reported updated results from its ongoing global Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma. As of October 14, 2026, among 33 efficacy evaluable patients, the confirmed objective response rate was 39% and median progression-free survival was 6.7 months. The company plans to advance MICVO into a global Phase 3 trial, planned to initiate in mid-2027.

Regulation FD disclosure, Other events
3 source passages
today announced updated results from its ongoing global Phase 1 monotherapy study evaluating micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC). The updated data, as of October 14, 2026, demonstrated a 39% confirmed objective response rate (cORR), 94% disease control rate (DCR), median progression-free survival (mPFS) of 6.7 months, 12-month overall survival (OS) probability of 81%, and newly reported median duration of response (mDOR) of 9.2 months among 33 efficacy evaluable patients Results support advancement of MICVO into the global Phase 3 HeadlinerSM trial in 2L+ R/M HNSCC, planned to initiate in mid-2027 Open the document at this passage
Nov 13
Current report 8-K
Authorized common shares increased from 190,000,000 to 380,000,000

Pyxis Oncology, Inc. stockholders approved increasing authorized common shares from 190,000,000 to 380,000,000, and the amendment became effective on November 13, 2026.

Charter or bylaw amendment, or fiscal year change, Shareholder vote results
2 source passages
On November 13, 2026 at Pyxis Oncology, Inc.’s (the “Company”) Special Meeting of Stockholders (the “Special Meeting”), the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to increase the number of authorized shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), from 190,000,000 shares to 380,000,000 shares (the “Authorized Share Increase”). On November 13, 2026, the Company filed a Certificate of Amendment to the Certificate of Incorporation (the “Charter Amendment”) with the Secretary of State of the State of Delaware to effect the Authorized Share Increase, which became effective upon filing. Open the document at this passage
Nov 10
Investor event
Pivotal trial set for second-line head and neck cancer

Pixis plans a 500-patient, one-to-one randomized pivotal trial in second-line head and neck cancer, with response rate and overall survival as primary endpoints and first patient dosing planned for the middle part of 2027.

3 source passages
I'm really privileged to be here representing our small but mighty Pixis team. We've had a really exciting 2026 so far. Really impressive data that we shared just a couple months ago, a couple fundraisings that have set us off on a path to stand up a pivotal trial in the middle part of 2027. Our plan and what we've disclosed in September is 500 patients randomized one-to-one for MICVO versus an investigator choice of docetaxel, methotrexate, or cetuximab. Primary endpoints would be response rate and overall survival. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
MICVO pivotal Phase 3 trial planned for mid-2027

Pyxis Oncology reported MICVO’s 36% confirmed ORR and 94% DCR in 2L+ R/M HNSCC, plans the global pivotal Phase 3 HeadlinerSM trial for mid-2027, and expects resources to fund operations into the first half of 2028.

Net loss $19.98M Diluted EPS -$0.24
Read from the MD&A section
4 source passages
Pyxis Oncology is a clinical-stage oncology company advancing a development strategy focused on addressing unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcinoma (HNSCC). Among the 33 efficacy evaluable patients, the confirmed ORR per RECIST v1.1 was 36% (12/33) and the DCR was 94% (31/33). In September 2026, we reported positive updated data from our Phase 1 monotherapy study in second-line and beyond (2L+) R/M HNSCC, which we believe support the advancement of MICVO into a pivotal program, and we plan to initiate HeadlinerSM, our global pivotal Phase 3 monotherapy trial in 2L+ R/M HNSCC, in mid-2027. We expect that our existing cash, cash equivalents and marketable debt securities, together with the net upfront proceeds from the public offering, will be sufficient to fund our operating expenses and capital expenditure requirements into the first half of 2028. Open the document at this passage
Nov 5
Current report 8-K
MICVO achieves 36% response rate; pivotal trial planned mid-2027

Pyxis Oncology reported a 36% confirmed objective response rate (12/33) for MICVO and plans to initiate the global Phase 3 HeadlinerSM trial in mid-2027. Cash plus net offering proceeds is expected to fund operations into the first half of 2028.

Financial results
3 source passages
Pyxis Oncology has aligned with feedback from the FDA and the EMA on the design of the global pivotal Phase 3 HeadlinerSM trial, which the Company plans to initiate in mid-2027. Confirmed objective response rate was 36% (12/33), and disease control rate was 94% (31/33). The Company believes its cash, cash equivalents, restricted cash and short-term investments as of September 30, 2026, together with the net upfront proceeds from the offering, will be sufficient to fund operations into the first half of 2028. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$86.71M
Trailing 12 months
Revenue growth YoY
-14.2%
Year over year
Operating margin
-609.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$55.57M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+33.5%
Year over year · more shares
Price change (1Y)
-60.0%
Trailing year
Short interest
3.8%
Latest settlement · 5.8 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross Death cross
Price vs 200-day avg −16%
below
Price vs 50-day avg −15%
below
RSI (14) 52
neutral
MACD trend Positive
52-week position 18%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +8%
trailing
6-month return +6%
trailing
YTD return +57%
this year
Relative strength +15%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) Death cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+33% holders QoQ · +39 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.78% of shares out · ▲ +4.1% MoM · 5.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
105 holders — near 3-yr high, broad support
Squeeze score 58
elevated · 0–100
Fundamentals
Weak
Revenue growth −14%
Y/Y
EPS growth +3%
Y/Y
Free cash flow $-63.5M
Balance sheet $15.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 126%
annualized · 1-yr
Max drawdown −80%
past year
ATR 9.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
Death cross Bearish
Price vs 200-day avg
−16% Bearish
Price vs 50-day avg
−15% Bearish
RSI (14)
52 Neutral
MACD trend
Positive Bullish
52-week position
18% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) Death cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+33% holders QoQ · +39 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.78% of shares out · ▲ +4.1% MoM · 5.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
105 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $2 · 18% Range high $5
vs 200-day avg -16% vs 50-day avg -15% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash and cash equivalents, including restricted cash, and short-term investments $57M As of September 30, 2026 —
Confirmed objective response rate 36% Phase 1 monotherapy data cutoff of August 18, 2026 —
Disease control rate 94% Phase 1 monotherapy data cutoff of August 18, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PYXS
Pyxis Oncology, Inc.
this stock
$216.49M +57.4% -14.2% — 3.8%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
105
% held
66.7%
Net QoQ
+45.6M sh
Top holder
GordonMD Global Investmen…
Held Float
View
Held by Funds
Fund positions
20
View
Short & Settlement
Short Interest Rising
Shares short
4.5M
Days to cover
5.8d
Change
+179.3K sh
View
Short Volume
Short vol %
41%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
3.0K
Value
$5.9K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
42.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$13.9M
Net income (FY)
$-79.6M
EPS diluted
$-1.28
View
Buybacks
Authorized
shares 2.7M
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 19, 2026
This year
26

Pyxis Oncology reported updated results from its ongoing global Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma. As of October 14, 2026, among 33 efficacy evaluable patients, the confirmed objective response rate was 39% and median progression-free survival was 6.7 months. The company plans to advance MICVO into a global Phase 3 trial, planned to initiate in mid-2027.

View
Proposed Sales
Value
$107.0K
Shares
35.0K
Filed
Jun 30, 2026
View
Exempt Offerings
Offering
$172.5M
Filed
Mar 22, 2021
View
Earnings & Events
Webcasts
Last webcast
Nov 19, 2026
View
Investor Relations
Latest news
Pyxis Oncology Reports Third Quar…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
PYXS +14.6% +7.7% +5.9% +0.0% +57.4%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +23.1% +17.0% +15.0% +8.7% +56.2%

Capital returns

Buyback program · as of Sep 30, 2022
Authorized
shares 2.74M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1782223 CUSIP 747324101 13F (30d) 107 filings 97 filers Visit website Investor relations